Could a common constipation drug help diabetics?

NCT ID NCT03119584

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether linaclotide (Linzess) can improve bowel movement frequency in people with type 2 diabetes who have chronic constipation. About 23 participants will receive either the drug or a placebo for two weeks, then switch after a break. The goal is to see if the drug safely increases spontaneous bowel movements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
linaclotide (Linzess)
What this could lead to
If it works, this could provide a safe, effective option for relieving chronic constipation in people with type 2 diabetes.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drug may cause side effects like diarrhea or abdominal pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC CONSTIPATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas Tech University Health Sciences Center

    El Paso, Texas, 79905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.